[The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019].
Congle Wen, Zhiwei Xie, Y. P. Li, Xilong Deng, X. T. Chen, Yi Cao, Ou Xu, Weiyin Lin, Feifei Li, W.-P. Cai, L. H. Li
Abstract
Antiviral treatment including LPV/r or arbidol or combination does not shorten the negative conversion time of 2019-nCoV nucleic acid nor improve clinical symptoms. Moreover, these antiviral drugs cause more adverse reactions which should be paid careful attention during the treatment.
Topics & Concepts
LopinavirMedicineRitonavirNucleic acid testInternal medicineLopinavir/ritonavirCoronavirus disease 2019 (COVID-19)DiseaseGastroenterologyViral loadVirologyVirusInfectious disease (medical specialty)Antiretroviral therapyPneumocystis jirovecii pneumonia detection and treatmentHematological disorders and diagnosticsCOVID-19 Clinical Research Studies